Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized trial of AMG 531 for chemotherapy-induced thrombocytopenia in advanced non-small cell lung cancer
2006-003699-36Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT), non-small cell lung cancer (NSCLC) and Large Cell Lung Carcinoma (LCLC) comparing AMG 531 arm with Placebo arm (2 arms). Primary endpoints: Safety of AMG 531 in treating chemotherapy-induced thrombocytopenia and Efficacy of AMG 531 dose and schedule in treating chemotherapy-induced thrombocytopenia. Started Oct 2006; status: completed.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)non-small cell lung cancer (NSCLC)Large Cell Lung Carcinoma (LCLC)
Beyond the preview
Go deeper on 2006-003699-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003699-36.